satralizumab · Medicine question

How does satralizumab block interleukin-6 signalling?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Satralizumab is a humanised IgG2 monoclonal antibody that binds to soluble and membrane-bound human interleukin-6 receptors, preventing downstream interleukin-6 signalling through these receptors.

Sources for this answer

Enspryng 120 mg solution for injection in pre-filled syringeRoche Products Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 3Document updated 15 May 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

Has the safety and efficacy of satralizumab been studied in patients with hepatic impairment?How much satralizumab does each Enspryng pre-filled syringe contain?What are the most frequently reported adverse reactions to satralizumab?What does the satralizumab solution in an Enspryng pre-filled syringe look like?What is known about the effects of satralizumab on fertility?When do injection-related reactions to satralizumab usually occur?

loading page…

Answer

Sources for this answer

More questions about satralizumab

Answer

Sources for this answer

More questions about satralizumab

satralizumab

More clinical questions?